The industry, patients, and clinicians should now seek a better understanding of the criteria and conditions, including any potential relationship with the health technology assessment review recommendations and any obligation on the company if DFMO does not successfully navigate the reimbursement process. …
Worth knowing the criteria used to justify the creation of the DFMO 'bridging' fund
July 16, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Most Australians want PBS medicine prices frozen or cut, poll finds
October 30, 2026 - - Latest News -
Canberra program shows young women where a future in health could take them
October 30, 2026 - - Latest News -
If only these patients needed a Spoodle, rather than a medicine
October 30, 2026 - - Latest News -
A hearing that provided more evidence of the need for meaningful change
October 29, 2026 - - Latest News -
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 - - Latest News -
Rebates and net spend are the major PBS story of the past decade
October 28, 2026 - - Latest News -
Astellas bets up to US$1.34 billion on Melbourne startup's cancer candidate
October 28, 2026 - - Latest News